Menu

Source Legend
  • Human-provided

    Entered or confirmed by an authorized person.

  • Google

    Imported Google information.

  • Trial-derived

    Calculated or extracted directly from associated trial records.

  • AI-inferred

    A capability inferred from trial history.

  • AI-extracted

    An explicit statement extracted from an official source.

  • Public registry

    Information from a public registry.

  • Site record

    Information held in the site record.

Source: Site record. MNJ Institute of Oncology & Regional Cancer Centre

Verified
Source: Site record.

Basic Information

Site Overview

Source: Human-provided.

MNJ Institute of Oncology & Regional Cancer Centre (MNJIO&RCC) is a major government cancer centre in Hyderabad with a strong focus on oncology care, research and academic activities. From a clinical research perspective, the institute provides access to a large and diverse oncology patient population and has multidisciplinary expertise across Medical Oncology, Surgical Oncology, Radiation Oncology, Pediatric Oncology, Gynecologic Oncology and other cancer specialties. Its diagnostic, pathology, molecular and imaging infrastructure can support clinical research activities, including oncology clinical trials, patient screening, treatment evaluation, sample-based research and long-term follow-up. The institute’s role as a regional referral centre makes it a potentially valuable site for investigator-initiated and industry-sponsored oncology research, particularly studies involving diverse cancer types and treatment modalities.

Business Status

Source: Human-provided. OPEN

Business Category

Source: Human-provided. location
Source: Trial-derived.
8Total Trials
Source: Trial-derived.
1Recruiting Trials
Source: Trial-derived.
3Active Trials
Source: Trial-derived.
4Completed Trials
Source: Trial-derived.
15Unique Conditions
Source: Trial-derived.
11Unique Sponsors

Affiliations

Conditions

Source: Trial-derived. Adenocarcinoma (1)Source: Trial-derived. Breast Neoplasms (1)Source: Trial-derived. Esophageal Adenocarcinoma (1)Source: Trial-derived. Fallopian Tube Neoplasms (1)Source: Trial-derived. Gastric Neoplasms (1)Source: Trial-derived. Gastroesophageal Adenocarcinoma (1)Source: Trial-derived. Gastrointestinal Neoplasms (1)Source: Trial-derived. Head and Neck Neoplasms (1)

Sponsors

Source: Trial-derived. Aurigene Discovery Technologies Limited (1)Source: Trial-derived. Bayer (1)Source: Trial-derived. BeOne Medicines LTD (1)Source: Trial-derived. BeOne Pharmaceutical Co., Ltd. (1)Source: Trial-derived. Boehringer Ingelheim (1)Source: Trial-derived. CanariaBio Inc. (1)Source: Trial-derived. Eisai Inc. (1)Source: Trial-derived. Imugene Limited (1)

Trial Phases

Historical Trial Phase Experience

Source: Human-provided. Phase I
Source: Human-provided. Phase II
Source: Human-provided. Phase IV
Source: Human-provided. Phase III

Research Team & Staffing

Research team size (total staff)

Source: Human-provided. 3

Principal investigators

Source: Human-provided. 6

Study coordinators

Source: Human-provided. 7

Laboratory & Biospecimens

Laboratory and biospecimen capabilities inferred from trial participation

Source: AI-inferred. Specimen packaging and shipment
Source: AI-inferred. Timed pharmacokinetic sampling and processing

Research Pharmacy & Investigational Product

Investigational-product capabilities inferred from trial participation

Source: AI-inferred. Hazardous / cytotoxic drug handling
Source: AI-inferred. Sterile preparation (laminar-flow hood / BSC or cleanroom)

Clinical Procedures

Clinical procedures inferred from trial participation

Source: AI-inferred. Intravenous infusion administration